about
The 1918 influenza pandemic: lessons for 2009 and the future.Pandemic and seasonal influenza: therapeutic challengesAn early 'classical' swine H1N1 influenza virus shows similar pathogenicity to the 1918 pandemic virus in ferrets and mice.Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hostsPrior infection with classical swine H1N1 influenza viruses is associated with protective immunity to the 2009 pandemic H1N1 virus.The PB2-E627K mutation attenuates viruses containing the 2009 H1N1 influenza pandemic polymeraseMultidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets.Detection of seasonal H3N2 influenza A virus by type-specific TaqMan minor groove binder probe assayObese mice have increased morbidity and mortality compared to non-obese mice during infection with the 2009 pandemic H1N1 influenza virus.Influenza in pregnancy.Bacterial coinfection in influenza: a grand rounds review.IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity.Rapid selection of a transmissible multidrug-resistant influenza A/H3N2 virus in an immunocompromised host.Glycosylation, hypogammaglobulinemia, and resistance to viral infectionsCritically ill patients with H7N9: new virus, old challenges*.Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study.In vivo evaluation of pathogenicity and transmissibility of influenza A(H1N1)pdm09 hemagglutinin receptor binding domain 222 intrahost variants isolated from a single immunocompromised patientEvaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model.The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts.Recent human influenza A/H3N2 virus evolution driven by novel selection factors in addition to antigenic drift.pH1N1 influenza A: timing is everything.Evaluation of Preexisting Anti-Hemagglutinin Stalk Antibody as a Correlate of Protection in a Healthy Volunteer Challenge with Influenza A/H1N1pdm Virus.Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat.Mosquito saliva: the hope for a universal arbovirus vaccine?Reliability, Validity, and Responsiveness of InFLUenza Patient-Reported Outcome (FLU-PRO©) Scores in Influenza-Positive Patients.723. Validation of a Wild-Type Influenza A/Texas-Like H3N2 Human Challenge Model with Comparison to the Validated A(H1N1)pdm09 ModelUsing the Influenza Patient-reported Outcome (FLU-PRO) diary to evaluate symptoms of influenza viral infection in a healthy human challenge modelDifferential Effects of Influenza Virus NA, HA Head, and HA Stalk Antibodies on Peripheral Blood Leukocyte Gene Expression during Human InfectionAntigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies
P50
Q30227352-C5BDA2F6-3A0D-49F8-B3BF-40BAE2A5B9E1Q30228856-45F1712F-0249-4C8C-9199-E1C2DAED5B5BQ30380435-2E4B3079-7CE3-4D96-9D47-E90120BA4737Q30387332-48A1A7F7-9436-4EB8-B4D7-E2F22E50AEBDQ30388369-293FA1E6-74F7-402E-8E1E-3E489DB75767Q30392368-4EE09263-E340-4347-AA91-A02A1ACA48F5Q30398271-855EC63B-A95C-4574-ABBE-37B0D8A0C463Q30401076-72C58380-8260-4A4C-B9DA-171FAF897530Q30403762-42E004AF-7293-4744-997B-9DCCA9E4A8FFQ30423910-D2A67472-8074-49AA-8C03-C8D744A94383Q30425954-BD33832F-0463-4268-B907-258DA239B10AQ33438726-3FC6DA4C-D0F5-422E-B9BC-18BF6DE1F56AQ33776525-925F5529-C450-4B34-B2A2-E550F16DF8F3Q33789632-E2268F44-82A0-4372-9333-FD225678AC30Q34988310-65723A24-678A-476D-BDA0-C9CA5C5CD379Q35127236-51836D85-8E2C-4F6B-84A1-2CD9C4418A0CQ35954143-127483C7-5F51-45F4-9DD1-FB37DB01E1C8Q37123064-7FB852F8-0884-48EE-AAF7-ABD8C1CA99FCQ37411707-58A41E08-51C0-464D-9BC9-D2774DF1C6D5Q37423915-03E0059F-B0EF-4739-BB68-9AB8677A9D9EQ42904862-33BC8668-AF28-4062-9996-81BF45C01DE5Q47549564-1E6886EE-9FE7-4ECA-951B-7612BF4EBEC2Q47561579-E92CB11E-606F-4A23-9769-C415D82261F7Q52607156-D928EA7B-7C33-4FBC-9A3B-D600DB1650EBQ52687028-DC8D50B1-926D-4370-A5FF-600D5F334184Q59327413-6B4D0974-9B4A-4E0C-9BD2-2D6267B44744Q59355804-901E8CED-20B9-4A60-B693-E0FA0D6D0DF9Q64056366-3CF92DF1-CF1E-4A36-9AB8-B5E55FA46BF6Q64064390-09DDF6C4-F7A3-4A78-9951-F46D732B8C16
P50
name
Matthew J Memoli
@en
type
label
Matthew J Memoli
@en
prefLabel
Matthew J Memoli
@en